Merck & Company Inc (MRK) - Total Assets
Based on the latest financial reports, Merck & Company Inc (MRK) holds total assets worth $128.69 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Merck & Company Inc (MRK) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Merck & Company Inc - Total Assets Trend (1985–2025)
This chart illustrates how Merck & Company Inc's total assets have evolved over time, based on quarterly financial data. See Merck & Company Inc net assets for net asset value and shareholders' equity analysis.
Merck & Company Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Merck & Company Inc's total assets of $128.69 Billion consist of 31.8% current assets and 68.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $14.56 Billion | 10.6% |
| Accounts Receivable | $12.68 Billion | 9.3% |
| Inventory | $6.66 Billion | 4.9% |
| Property, Plant & Equipment | $26.82 Billion | 19.6% |
| Intangible Assets | $26.68 Billion | 19.5% |
| Goodwill | $21.58 Billion | 15.8% |
Asset Composition Trend (1985–2025)
This chart illustrates how Merck & Company Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Merck & Company Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Merck & Company Inc's current assets represent 31.8% of total assets in 2025, a decrease from 47.1% in 1985.
- Cash Position: Cash and equivalents constituted 10.6% of total assets in 2025, down from 17.2% in 1985.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 34.0% of total assets, an increase from 1.0% in 1985.
- Asset Diversification: The largest asset category is property, plant & equipment at 19.6% of total assets.
Merck & Company Inc Competitors by Total Assets
Key competitors of Merck & Company Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
AstraZeneca PLC
NYSE:AZN
|
USA | $114.02 Billion |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
Brazil | R$3.66 Billion |
|
AstraZeneca PLC
F:ZEGA
|
Germany | €114.46 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$2.28 Million |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$112.48 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$207.62 Billion |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436
|
China | CN¥18.38 Billion |
|
Sichuan Kelun Pharmaceutical Co Ltd
SHE:002422
|
China | CN¥41.14 Billion |
Merck & Company Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.30 | 1.41 | 1.31 |
| Quick Ratio | 1.06 | 1.16 | 0.95 |
| Cash Ratio | 0.00 | 0.34 | 0.39 |
| Working Capital | $8.07 Billion | $10.33 Billion | $6.76 Billion |
Merck & Company Inc - Advanced Valuation Insights
This section examines the relationship between Merck & Company Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.41 |
| Latest Market Cap to Assets Ratio | 2.18 |
| Asset Growth Rate (YoY) | 16.9% |
| Total Assets | $136.87 Billion |
| Market Capitalization | $298.26 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Merck & Company Inc's assets at a significant premium (2.18x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Merck & Company Inc's assets grew by 16.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Merck & Company Inc (1985–2025)
The table below shows the annual total assets of Merck & Company Inc from 1985 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $136.87 Billion | +16.87% |
| 2024-12-31 | $117.11 Billion | +9.78% |
| 2023-12-31 | $106.67 Billion | -2.28% |
| 2022-12-31 | $109.16 Billion | +3.28% |
| 2021-12-31 | $105.69 Billion | +15.40% |
| 2020-12-31 | $91.59 Billion | +8.52% |
| 2019-12-31 | $84.40 Billion | +2.13% |
| 2018-12-31 | $82.64 Billion | -5.96% |
| 2017-12-31 | $87.87 Billion | -7.87% |
| 2016-12-31 | $95.38 Billion | -6.20% |
| 2015-12-31 | $101.68 Billion | +3.58% |
| 2014-12-31 | $98.17 Billion | -7.08% |
| 2013-12-31 | $105.64 Billion | -0.46% |
| 2012-12-31 | $106.13 Billion | +0.96% |
| 2011-12-31 | $105.13 Billion | -0.62% |
| 2010-12-31 | $105.78 Billion | -5.82% |
| 2009-12-31 | $112.31 Billion | +137.98% |
| 2008-12-31 | $47.20 Billion | -2.39% |
| 2007-12-31 | $48.35 Billion | +8.48% |
| 2006-12-31 | $44.57 Billion | -0.62% |
| 2005-12-31 | $44.85 Billion | +5.34% |
| 2004-12-31 | $42.57 Billion | +4.89% |
| 2003-12-31 | $40.59 Billion | -14.66% |
| 2002-12-31 | $47.56 Billion | +8.04% |
| 2001-12-31 | $44.02 Billion | +10.30% |
| 2000-12-31 | $39.91 Billion | +12.00% |
| 1999-12-31 | $35.63 Billion | +11.87% |
| 1998-12-31 | $31.85 Billion | +23.77% |
| 1997-12-31 | $25.74 Billion | +5.94% |
| 1996-12-31 | $24.29 Billion | +1.94% |
| 1995-12-31 | $23.83 Billion | +9.04% |
| 1994-12-31 | $21.86 Billion | +9.68% |
| 1993-12-31 | $19.93 Billion | +79.75% |
| 1992-12-31 | $11.09 Billion | +16.71% |
| 1991-12-31 | $9.50 Billion | +18.29% |
| 1990-12-31 | $8.03 Billion | +18.84% |
| 1989-12-31 | $6.76 Billion | +10.27% |
| 1988-12-31 | $6.13 Billion | +7.88% |
| 1987-12-31 | $5.68 Billion | +11.26% |
| 1986-12-31 | $5.11 Billion | +4.14% |
| 1985-12-31 | $4.90 Billion | -- |
About Merck & Company Inc
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, a… Read more